🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib

    The George Institute

    Undifferentiated pleomorphic sarcoma and Dedifferentiated liposarcoma

    phase 2 small molecule active

    1 trial

  2. Olaparib, Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  3. Olatorepatide

    Regeneron UK Limited

    Overweight or Obesity

    phase 2 small molecule active

    1 trial

  4. Oleclumab, INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., Datopotamab deruxtecan, PACLITAXEL, Capivasertib, DS-8201a

    AstraZeneca AB

    First-line (1L) Stage IV Triple Negative Breast Cancer (TNBC) - the subtype of breast cancer characterized by a lack of tumor expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2.

    phase 2 small molecule active

    1 trial

  5. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  6. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Chronic Myelomonocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  7. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Mutant IDH1 Inhibitor Olutasidenib

    phase 2 small molecule active

    1 trial

  8. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  9. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Targeted Therapy

    phase 2 small molecule active

    1 trial

  10. Olutasidenib + TMZ

    RIGEL PHARMACEUTICALS INC

    High Grade Glioma

    phase 2 small molecule active

    1 trial

  11. Omacetaxine

    Teva Pharma GmbH

    Acute Myelogenous Leukemia (AML)

    phase 2 small molecule terminated

    1 trial

  12. Omomyc

    The George Institute

    Advanced High-Grade Osteosarcoma

    phase 2 small molecule active

    1 trial

  13. OncoTICE® powder for instillation fluid for intravesical use containing 2-8 x 108 CFU Tice BCG., N-803 (NAI), OncoTICE® 2-8 x 108 vermehrungsfähige Einheiten Pulver zur Herstellung einer Suspension zur intravesikalen Instillation

    Immunitybio Ireland Limited

    Non-Muscle Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  14. Ontruzant 420 mg powder for concentrate for solution for infusion, Oxaliplatin onkovis 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, TAXOTERE 20 mg/1 ml concentrate for solution for infusion, Oncofolic 50 mg/ml, Injektions-/Infusionslösung, 5-FU medac 50 mg/ml, Injektionslösung

    The George Institute

    HER2-positive, localized esophagogastric adenocarcinoma

    phase 2 small molecule active

    1 trial

  15. Opaganib

    Apogee Therapeutics

    Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  16. Osimertinib 80 mg/40 mg

    AstraZeneca

    Stage II-IIIB Non-small Cell Lung Carcinoma

    phase 2 small molecule active

    1 trial

  17. Oxaliplatin

    Regeneron UK Limited

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  18. Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, 5-FU medac 50 mg/ml, Injektionslösung, DS-8201a

    The George Institute

    HER2 positive resectable esophagogastric adenocarcinoma

    phase 2 small molecule active

    1 trial

  19. Ozempic 0.25 mg solution for injection in pre-filled pen, Ozempic 0.5 mg solution for injection in pre-filled pen, Ozempic 1 mg solution for injection in pre-filled pen

    The George Institute

    Craving for and use of chemsex-related drugs

    phase 2 small molecule active

    1 trial

  20. PACLITAXEL , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL , Lenvatinib, BEVACIZUMAB , CAPECITABINE , CARBOPLATIN , FLUOROURACIL , OXALIPLATIN , GEMCITABINE , CISPLATIN , MK-7684A, Lenvatinib

    Merck Sharp and Dohme

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  21. PACLITAXEL , Lenvatinib, MK-4830, FAMOTIDINE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, PARACETAMOL , IRINOTECAN , -, Lenvatinib, -, MK-2870

    Merck Sharp and Dohme

    Advanced esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  22. PACLITAXEL ALBUMIN-BOUND, NIVOLUMAB, GEMCITABINE, IPILIMUMAB, SOTORASIB, ODM-212 5 mg coated tablet, ODM-212 40 mg coated tablet

    Orion Laboratories Pty.

    Neoplasms benign malignant and unspecified (incl. cysts and polyps)

    phase 2 small molecule active

    1 trial

  23. PACLITAXEL ALBUMIN-BOUND, PACLITAXEL , DOCETAXEL , Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion., mRNA-4157, CARBOPLATIN

    Merck Sharp and Dohme

    Non-small cell lung cancer stage IV

    phase 2 small molecule active

    1 trial

  24. PACLITAXEL, Durvalumab_IJB, CARBOPLATIN, Oleclumab_IJB

    The George Institute

    Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources